Skip to main content

Eicosanoids and Nitric Oxide: Mediators of Cardiovascular, Cerebral & Neoplastic Diseases

Objective

The Eicosanoids and nitric oxide (NO) are important signalling molecules in many physiological and pathological pro-cesses, including cardiovascular, cerebral and neoplastic disorders. Together, these diseases account for the vast maj-ority of deaths in Europe and represent an enormous health problem with a major socio-economic impact. We have assembled a large and highly competitive Consortium, positioned at the forefront of eicosanoid and NO research. The partners will jointly carry out an ambitious project, aiming to increase the knowledge of these autacoids, with the goal to develop novel therapeutic strategies and medical treatments.
We will carry out molecular studies on key enzymes and receptors to elucidate biochemical properties, catalytic mechan-isms and structure-function relationships. We will address the functional genomics of the Eicosanoid and NO cascades to characterize gene expression profiles and regulation under normal and disease states, and identify novel potential drug targets. New genes will be characterized using proteomics, structural genomics and model organisms. In parallel, the partners will conduct cell biological work on gene regulation, gene silencing, signalling systems and cross-talk between pathways. This information will be used in studies of disease mechanisms such as inflammation, immune responses and angiogenesis. In turn, these insights in pathology will be translated into investigations of diseases using animal models and clinical applications.
The basic research together with applied and clinical studies will act in synergy to identify novel targets for pharmacolo-gical intervention and drug design for the treatment of patients suffering from cardiovascular, cerebral and neoplastic disorders. Moreover, our Consortium will work in alliance with industry and is expected to generate an integrated infra-structure for R&D, training and mobility of researchers, exploitation and dissemination.

Call for proposal

FP6-2003-LIFESCIHEALTH-I
See other projects for this call

Coordinator

KAROLINSKA INSTITUTET
Address

Stockholm
Sweden

See on map

Participants (12)

UNIVERSITY OF FRANKFURT
Germany
Address
Senckenberganlage 31
Frankfurt

See on map

UNIVERSITÀ DEGLI STUDI DI MILANO
Italy
Address
Via Festa Del Perdono 7
Milano

See on map

FONDAZIONE UNIVERSITA' "GABRIELE D'ANNUNZIO"'
Italy
Address
Via Dei Vestini, 31
Chieti Scalo

See on map

UNIVERSITY COLLEGE LONDON
United Kingdom
Address
University College London, Gower Street
London

See on map

QUEEN MARY & WESTFIELD COLLEGE, UNIVERSITY OF LONDON
United Kingdom
Address
Mile End Road
London

See on map

NATIONAL UNIVERSITY OF IRELAND, DUBLIN
Ireland
Address
Belfield
Dublin 4

See on map

NICOX RESEARCH INSTITUTE SRL
Italy
Address
Via Ariosto 21
20091 Bresso - Milano

See on map

UNIVERSIDAD AUTONOMA DE MADRID
Spain
Address
Cantoblanco
Madrid

See on map

BIOLIPOX AB
Sweden
Address
-
6280 Stockholm

See on map

QUEEN'S UNIVERSITY
Canada
Address
99 University Avenue
Kingston, Ontario

See on map

CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN
Germany
Address
Schumannstraße 20-21
Berlin

See on map

OREXO AB
Sweden
Address
Virdings Allé 32 A
303 Uppsala

See on map